Gene · 7516
Papers1,770
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 1,770
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Roles of homologous recombination in response to ionizing radiation-induced DNA damage. | Int J Radiat Biol | 2023 | 34283012 | PubTator, text mining | PubMed |
| Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects. | Cancer Res Commun | 2022 | 36970052 | PubTator, text mining | PubMed |
| Drug-gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition. | Cancer Res Commun | 2022 | 36969741 | PubTator, text mining | PubMed |
| Synthetic lethal interactions of DEAD/H-box helicases as targets for cancer therapy. | Front Oncol | 2022 | 36761420 | PubTator, text mining | PubMed |
| Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer. | Front Genet | 2022 | 36733939 | PubTator, text mining | PubMed |
| Frequency of Pathogenic Germline Mutations in Early and Late Onset Familial Breast Cancer Patients Using Multi-Gene Panel Sequencing: An Egyptian Study. | Genes (Basel) | 2022 | 36672847 | PubTator, text mining | PubMed |
| Gene polymorphisms and prognosis of head and neck squamous cell carcinoma: a systematic review. | Rep Pract Oncol Radiother | 2022 | 36632296 | PubTator, text mining | PubMed |
| Gene Expression Profiling Elucidates Cellular Responses to NCX4040 in Human Ovarian Tumor Cells: Implications in the Mechanisms of Action of NCX4040. | Cancers (Basel) | 2022 | 36612280 | PubTator, text mining | PubMed |
| Evolutionary Analysis of TCGA Data Using Over- and Under- Mutated Genes Identify Key Molecular Pathways and Cellular Functions in Lung Cancer Subtypes. | Cancers (Basel) | 2022 | 36612014 | PubTator, text mining | PubMed |
| Germline mutations in high penetrance genes are associated with worse clinical outcomes in patients with non-small cell lung cancer. | JTCVS Open | 2022 | 36590722 | PubTator, text mining | PubMed |
| Targeting the DNA Damage Response Machinery for Lung Cancer Treatment. | Pharmaceuticals (Basel) | 2022 | 36558926 | PubTator, text mining | PubMed |
| The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review. | Cancers (Basel) | 2022 | 36551737 | PubTator, text mining | PubMed |
| Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutations. | BMC Cancer | 2022 | 36544182 | PubTator, text mining | PubMed |
| CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors. | J Exp Clin Cancer Res | 2022 | 36539830 | PubTator, text mining | PubMed |
| DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities. | Int J Mol Sci | 2022 | 36499000 | PubTator, text mining | PubMed |
| Immunological and Genomic Analysis Reveals Clinically Relevant Distinctions between Angiosarcoma Subgroups. | Cancers (Basel) | 2022 | 36497420 | PubTator, text mining | PubMed |
| Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality. | Cancers (Basel) | 2022 | 36497275 | PubTator, text mining | PubMed |
| Epigenetic Regulation in Chromium-, Nickel- and Cadmium-Induced Carcinogenesis. | Cancers (Basel) | 2022 | 36497250 | PubTator, text mining | PubMed |
| Genomic signature of Fanconi anaemia DNA repair pathway deficiency in cancer. | Nature | 2022 | 36450981 | PubTator, text mining | PubMed |
| Chemotherapeutic Resistance Genes of Breast Cancer Patients - An Overview. | Adv Pharm Bull | 2022 | 36415633 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7516/papers?page=13